|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 581.43 USD | +0.50% |
|
-0.18% | +19.16% |
| 04-14 | United Therapeutics Insider Sold Shares Worth $5,748,802, According to a Recent SEC Filing | MT |
| 04-13 | United Therapeutics Insider Sold Shares Worth $5,408,194, According to a Recent SEC Filing | MT |
Business description: United Therapeutics Corporation
Number of employees: 1,400
Sales by Activity: United Therapeutics Corporation
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
Pharmaceuticals | 1.69B | 1.94B | 2.33B | 2.88B | 3.18B |
Geographical breakdown of sales: United Therapeutics Corporation
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
United States | 1.56B | 1.81B | 2.2B | 2.74B | 3.04B |
Rest of World | 121M | 122M | 125M | 138M | 146M |
Executive Committee: United Therapeutics Corporation
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 71 | 1996-06-25 | |
| President | 54 | 2016-06-25 | |
James Edgemond
DFI | Director of Finance/CFO | 58 | 2015-03-12 |
Dewey Steadman
IRC | Investor Relations Contact | - | 2018-12-31 |
Paul Mahon
LAW | General Counsel | 62 | 1996-06-25 |
Composition of the Board of Directors: United Therapeutics Corporation
| Director | Title | Age | Since |
|---|---|---|---|
Raymond Kurzweil
BRD | Director/Board Member | 78 | 2001-12-31 |
| Chairman | 71 | 1996-06-25 | |
Louis Sullivan
BRD | Director/Board Member | 92 | 2001-12-31 |
Raymond Dwek
BRD | Director/Board Member | 84 | 2001-12-31 |
| Director/Board Member | 62 | 2002-10-23 | |
| Director/Board Member | 63 | 2002-12-31 | |
Richard Giltner
BRD | Director/Board Member | 62 | 2009-04-28 |
Tommy Thompson
BRD | Director/Board Member | 83 | 2009-12-31 |
Judy Olian
BRD | Director/Board Member | 74 | 2015-06-25 |
Nilda Mesa
BRD | Director/Board Member | 66 | 2018-10-30 |
Company details: United Therapeutics Corporation
Other Pharmaceuticals
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.50% | -0.18% | +103.86% | +152.06% | 25.36B | |
| -2.45% | -5.40% | +19.11% | +142.20% | 825B | |
| -1.00% | -1.53% | +54.68% | +43.43% | 578B | |
| -0.51% | -2.26% | +16.97% | +28.31% | 372B | |
| -0.14% | +1.38% | +25.39% | +13.94% | 326B | |
| -1.02% | -2.96% | +43.64% | +24.88% | 314B | |
| -1.72% | -4.42% | +50.18% | +2.37% | 296B | |
| -1.61% | -2.34% | +31.20% | +34.32% | 294B | |
| -1.07% | -0.89% | +17.40% | +39.75% | 189B | |
| -0.59% | -1.38% | +32.08% | +66.90% | 174B | |
| Average | -0.87% | +0.85% | +39.45% | +54.82% | 339.46B | |
| Weighted average by Cap. | -1.21% | +0.31% | +32.77% | +58.69% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- UTHR Stock
- Company United Therapeutics Corporation
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition